Orphan designation: Human coagulation factor X Treatment of acquired factor X deficiency, 12/01/2024 Positive
Retrieved on:
Thursday, April 18, 2024
EU/3/23/2886 - orphan designation for treatment of acquired factor X deficiency
Key Points:
- EU/3/23/2886 - orphan designation for treatment of acquired factor X deficiency
Human coagulation factor X
OrphanHuman
BPL Bioproducts Laboratory GmbH
EMA publishes information on orphan medicinal product designation adopted by the Committee for Orphan Medicinal Products (COMP) on the IRIS online platform:
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases. - The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: